Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On August 15 and 16, 2024, Rothblatt exercised stock options and sold shares of United Therapeutics common stock.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The exercise price for the options was $129.49 per share.
- The sales prices ranged from $317.73 to $326.38 per share.
- A total of 7,200 stock options were exercised across the two days.
- The trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- Rothblatt also holds shares indirectly through various family trusts.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by a company executive under a pre-arranged plan, indicating a neutral sentiment.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of 723,869 stock options expiring December 31, 2024.
Industry Context
Executive stock sales are common and often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan provides a legal framework for these transactions.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- The use of 10b5-1 trading plans is a standard practice among public company executives to manage their stock holdings.
- Comparing Rothblatt's stock option exercises and sales to those of executives at similar-sized biotech companies (e.g., Vertex Pharmaceuticals, Regeneron) could provide context on the scale and frequency of such transactions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date exercisable for stock options |
| 08/04/2023 | Date the 10b5-1 trading plan was entered into |
| 08/15/2024 | Date of first reported transaction (exercise and sale of stock) |
| 08/16/2024 | Date of second reported transaction (exercise and sale of stock) |
| 08/31/2024 | End date of the 10b5-1 trading plan (if options are not exhausted) |
| 12/31/2024 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.